Edward van Wezel is the Founder and Managing Partner of BioGeneration Ventures (BGV). See sector focus and contact routes.
Edward van Wezel is the Founder and Managing Partner of BioGeneration Ventures (BGV), a European venture capital firm he launched in 2006 that has managed over €250 million across four funds. His background includes early work as a process engineer at Chiron Inc., product development roles at Johnson & Johnson, and serving as CEO of multiple life sciences companies in the Netherlands since 2000. BGV’s investment thesis targets early-stage life sciences companies, specifically seed and pre-seed pharmaceutical developers in drug discovery and therapeutic development with convincing experimental data, focusing on the European market. Typical check sizes range up to €105 million, and van Wezel often takes an active, supportive role in biotech innovation, frequently serving on supervisory boards of portfolio companies. Notable portfolio companies include Acerta Pharma (acquired by AstraZeneca), TigaTx, Confo Therapeutics, and Scenic Biotech, all of which he has invested in or served on their boards. A distinctive point of view is his emphasis on translational research and addressing unmet medical needs through groundbreaking medical innovations, reflecting his
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Naarden.
Investors like Edward van Wezel · Full investor directory · Investor access · Company funding database